Methods of using adipose derived stem cells to promote wound healing

• US 8,105,580 B2
• Filed: 07/01/2004
• Issued: 01/31/2012
• Est. Priority Date: 12/07/2001
• Status: Expired due to Fees

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H., Daniels, Eric
• Primary Examiner(s): Lankford, Jr., Blaine
• Application Number:
  US10/884,860
• Publication Number:
  US 20050048034A1
• Time in Patent Office: 2,770 Days
• Field of Search: 424/93.7
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61L 15/40 containing ingredients of undetermined constitution or reaction products thereof , e.g. plant or animal extracts
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 : Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1384 : from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 : Vascular Endothelial cells

Abstract

Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims

1. A method of accelerating the healing of a wound of the skin of a subject, comprising:

identifying a subject having a wound of the skin; and

providing adipose tissue to a self contained adipose-derived stem cell processing unit comprising;

a tissue collecting container configured to receive and fully or partially disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which said fully or partially disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment; and

wherein said cell collection container, further comprises a cell concentrator that facilitates separation of the cells in a suspension; and

an outlet that is structured to permit said concentrated population of cells comprising adipose-derived cells to be removed from said stem cell processing unit;

obtaining a concentrated population of cells comprising adipose-derived stem cells from said self contained adipose-derived stem cell processing unit; and

providing said concentrated population of cells comprising adipose-derived stem cells to said subject in an amount sufficient to accelerate the healing of said wound.

2. The method of claim 1, wherein said subject is a diabetic.

3. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without further purification.

4. The method of claim 1, wherein the wound is a non healing diabetic wound.

5. The method of claim 3, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without culturing the cells before administering them to said subject.

6. The method of claim 1, wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the subject.

7. The method of claim 1, further comprising providing an additive to said concentrated population of cells comprising adipose-derived stem cells.

16. The method of claim 1, wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.

18. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a bolus.

20. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a multiple doses.

22. The method of claim 7, wherein said additive is an immunosuppressive agent.

24. The method of claim 1, wherein at least a portion of said concentrated population of cells comprising adipose-derived stem cells is provided directly to the wound of the skin.

26. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is derived from adipose tissue from said subject.

28. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells comprises at least about 1×

10⁵ to about 1×

10⁷ cells/mL.

30. The method of claim 1, wherein said cell concentrator is a centrifuge.

31. The method of claim 30, wherein said centrifuge is disposed within said cell collection container.

8. A method of accelerating the healing of a wound of the skin of a subject, comprising:

identifying a subject having a wound of the skin; and

providing adipose tissue to a self contained adipose-derived stem cell processing unit comprising;

a tissue collection chamber that is configured to receive a first portion of unprocessed adipose tissue from said subject while maintaining a closed system, wherein said tissue collection chamber comprises an aspiration port structured to be coupled to a suction device;

a first filter that is disposed within said tissue collection chamber, wherein said first filter is configured to retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter substantially separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises lipid, blood, mature adipocytes and saline;

a processing chamber that is joined to said tissue collection chamber by a conduit such that a closed system is maintained, wherein said processing chamber comprises a second filter, a centrifuge, or a spinning membrane filter;

a programmable processing device capable of communication with said tissue collection chamber and said processing chamber, wherein said processing device operates at least one pump configured to use pressure to control ingress and egress of tissues through said automated adipose-derived stem cell processing unit; and

an outlet wherein said outlet is configured to allow the aseptic removal of a concentrated population of cells comprising adipose-derived stem cells obtained from said processing chamber;

obtaining a concentrated population of cells comprising adipose-derived stem cells from said self contained adipose-derived stem cell processing unit; and

providing said concentrated population of cells comprising adipose-derived stem cells to said subject in an amount sufficient to accelerate the healing of said wound.

9. The method of claim 8, wherein said subject is a diabetic.

10. The method of claim 8, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without further purification.

11. The method of claim 8, wherein the wound is a non healing diabetic wound.

12. The method of claim 10, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without culturing the cells before administering them to said subject.

13. The method of claim 8, wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the subject.

14. The method of claim 8, further comprising providing an additive to said concentrated population of cells comprising adipose-derived stem cells.

15. The method of claim 14, wherein said additive comprises one or more angiogenic factors.

17. The method of claim 8, wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.

19. The method of claim 8, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a bolus.

21. The method of claim 8, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a multiple doses.

23. The method of claim 14, wherein said additive is an immunosuppressive agent.

25. The method of claim 8, wherein at least a portion of said concentrated population of cells comprising adipose-derived stem cells is provided directly to the wound of the skin.

27. The method of claim 8, wherein said concentrated population of cells comprising adipose-derived stem cells is derived from adipose tissue from said subject.

29. The method of claim 8, wherein said concentrated population of cells comprising adipose-derived stem cells comprises at least about 1×

10⁵ to about 1×

10⁷ cells/mL.

32. The method of claim 8, wherein said processing chamber comprises a centrifuge.

33. The method of claim 32, wherein said centrifuge is disposed within said processing chamber.